GlucoTrack shares surge 49.56% premarket after USPTO approves patents for CBGM platform.

GlucoTrack (NASDAQ: GCTK) surged 49.56% in premarket trading following the U.S. Patent and Trademark Office’s (USPTO) approval of three key patents for its continuous blood glucose monitoring (CBGM) platform. The patents, covering proprietary sensor chemistry, intravascular lead design, and low-power electronics, reinforce the company’s intellectual property portfolio and advance its commercialization strategy for a fully implantable, multi-year CBGM system. The CEO emphasized that these approvals establish competitive barriers and support the company’s differentiated approach to diabetes management, as the technology directly measures blood glucose (rather than interstitial fluid) to eliminate lag time. The news aligns with the stock’s sharp premarket rise, reflecting investor optimism over strengthened IP protection and progress toward long-term commercial viability.